OBJECTIVES: Thyrotropin-secreting pituitary adenoma (TSHoma) is rare and it is also a rare cause of thyrotoxicosis. Failure to detect the presence of TSHoma may result in dramatic consequences. This study is a review of our experience in the management of TSHoma at Huashan Hospital, China. METHODS: We followed up eight patients with TSHoma (five males and three females) between 2006 and 2011. The patients' medical records were retrieved, and the demographic data, clinical presentation and management, final outcomes and follow-up were reviewed, and surgery performed. RESULTS: All the eight patients had unsuppressed TSH levels with elevated thyroid hormone levels; and neuroimaging revealed pituitary lesions. Five patients (62.5 %) were previously misdiagnosed as primary hyperthyroidism. They received pituitary adenomectomy, somatostatin analogs, and/or radiotherapy after definitive diagnosis. Serum TSH and thyroid hormone levels of all the patients restored to the normal levels during the follow-up. CONCLUSIONS: Adenomectomy is not curative in many TSHoma patients, it should be adjuvantly treated by pharmacological and/or radiotherapy, frequently. A combination of adenomectomy, somatostatin analogs, and radiotherapy is often required for long-term management of the disease.
OBJECTIVES: Thyrotropin-secreting pituitary adenoma (TSHoma) is rare and it is also a rare cause of thyrotoxicosis. Failure to detect the presence of TSHoma may result in dramatic consequences. This study is a review of our experience in the management of TSHoma at Huashan Hospital, China. METHODS: We followed up eight patients with TSHoma (five males and three females) between 2006 and 2011. The patients' medical records were retrieved, and the demographic data, clinical presentation and management, final outcomes and follow-up were reviewed, and surgery performed. RESULTS: All the eight patients had unsuppressed TSH levels with elevated thyroid hormone levels; and neuroimaging revealed pituitary lesions. Five patients (62.5 %) were previously misdiagnosed as primary hyperthyroidism. They received pituitary adenomectomy, somatostatin analogs, and/or radiotherapy after definitive diagnosis. Serum TSH and thyroid hormone levels of all the patients restored to the normal levels during the follow-up. CONCLUSIONS: Adenomectomy is not curative in many TSHoma patients, it should be adjuvantly treated by pharmacological and/or radiotherapy, frequently. A combination of adenomectomy, somatostatin analogs, and radiotherapy is often required for long-term management of the disease.
Authors: H Valdes Socin; P Chanson; B Delemer; A Tabarin; V Rohmer; J Mockel; A Stevenaert; A Beckers Journal: Eur J Endocrinol Date: 2003-04 Impact factor: 6.664
Authors: Yamei Yang; Jie Liu; Kan Deng; Lin Lu; Huijuan Zhu; Xiaolan Lian; Xinjie Bao; Lian Duan; Yong Yao Journal: Front Endocrinol (Lausanne) Date: 2021-12-23 Impact factor: 5.555